Evidence map›Paper›PMID 23986440›Full record

ArticleThe Journal of biological chemistry2013

Arylsulfatase K, a novel lysosomal sulfatase.

Elena Marie Wiegmann, Eva Westendorf, Ina Kalus, Thomas H Pringle, Torben Lübke, Thomas Dierks

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Mucopolysaccharidoses and the blood-brain barrier.Fluids and barriers of the CNS · 2022
    Review
  7. Article
  8. Modelling of hypoxia gene expression for three different cancer cell lines.International journal of computational biology and drug design · 2020
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Elena Marie WiegmannFrom the Department of Chemistry, Biochemistry I, Bielefeld University, 33615 Bielefeld, Germany and.
Eva WestendorfFrom the Department of Chemistry, Biochemistry I, Bielefeld University, 33615 Bielefeld, Germany and.
Ina KalusFrom the Department of Chemistry, Biochemistry I, Bielefeld University, 33615 Bielefeld, Germany and.
Thomas H Pringlethe Sperling Foundation, Eugene, Oregon 97405.
Torben LübkeFrom the Department of Chemistry, Biochemistry I, Bielefeld University, 33615 Bielefeld, Germany and.
Thomas DierksFrom the Department of Chemistry, Biochemistry I, Bielefeld University, 33615 Bielefeld, Germany and. Electronic address: thomas.dierks@uni-bielefeld.de.
Bielefeld University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human sulfatase family has 17 members, 13 of which have been characterized biochemically. These enzymes specifically hydrolyze sulfate esters in glycosaminoglycans, sulfolipids, or steroid sulfates, thereby playing key roles in cellular degradation, cell signaling, and hormone regulation. The loss of sulfatase activity has been linked to severe pathophysiological conditions such as lysosomal storage disorders, developmental abnormalities, or cancer. A novel member of this family, arylsulfatase K (ARSK), was identified bioinformatically through its conserved sulfatase signature sequence directing posttranslational generation of the catalytic formylglycine residue in sulfatases. However, overall sequence identity of ARSK with other human sulfatases is low (18-22%). Here we demonstrate that ARSK indeed shows desulfation activity toward arylsulfate pseudosubstrates. When expressed in human cells, ARSK was detected as a 68-kDa glycoprotein carrying at least four N-glycans of both the complex and high-mannose type. Purified ARSK turned over p-nitrocatechol and p-nitrophenyl sulfate. This activity was dependent on cysteine 80, which was verified to undergo conversion to formylglycine. Kinetic parameters were similar to those of several lysosomal sulfatases involved in degradation of sulfated glycosaminoglycans. An acidic pH optimum (~4.6) and colocalization with LAMP1 verified lysosomal functioning of ARSK. Further, it carries mannose 6-phosphate, indicating lysosomal sorting via mannose 6-phosphate receptors. ARSK mRNA expression was found in all tissues tested, suggesting a ubiquitous physiological substrate and a so far non-classified lysosomal storage disorder in the case of ARSK deficiency, as shown before for all other lysosomal sulfatases.

Indexed as

ArylsulfatasesGene ExpressionGlycoproteinsHEK293 CellsHumansHydrogen-Ion ConcentrationKineticsLysosomal Storage DiseasesLysosomesSubstrate SpecificityARSK protein, humanArylsulfatasesGlycoproteinsARSKArylsulfatase KEnzyme KineticsEnzyme ProcessingLysosomal GlycoproteinsLysosomal Storage DiseaseLysosomesProtein SortingSulfatase

Identifiers

PMID23986440
PMCPMC3798471
OpenAlexW2037972557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.